Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The Heterozygous familial hypercholesterolemia (heFH) pipeline drugs market research report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for heFH and features dormant and discontinued projects.
heFH Pipeline Drugs Market Segmentation by Targets
Some of the key targets of the heFH pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Angiopoietin Related Protein 3, ATP Citrate Synthase (ATP Citrate, Cholesteryl Ester Transfer Protein, and Type 1 Angiotensin II Receptor.
heFH Pipeline Drugs Market Analysis, by Targets
For more heFH pipeline drugs market target insights, download a free report sample
heFH Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the heFH pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Angiopoietin Related Protein 3 Inhibitor, ATP Citrate Synthase (ATP Citrate Inhibitor, Cholesteryl Ester Transfer Protein Inhibitor, and Type 1 Angiotensin II Receptor Antagonist.
heFH Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanism of action insights into the heFH pipeline drugs market, download a free report sample
heFH Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the heFH pipeline drugs market are subcutaneous, intravenous, and oral.
heFH Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the heFH pipeline drugs market, download a free report sample
heFH Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the heFH pipeline drugs market are monoclonal antibody, gene therapy, small molecule, antisense RNAi oligonucleotide, and fusion protein.
heFH Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the heFH pipeline drugs market, download a free report sample
heFH Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the heFH pipeline drugs market are Verve Therapeutics Inc, Regeneron Pharmaceuticals Inc, Akeso Inc, Amgen Inc, Beijing Mabworks Biotech Co Ltd, Daewoong Pharmaceutical Co Ltd, Epicrispr Biotechnologies Inc, Esperion Therapeutics Inc, Innovent Biologics Inc, and LIB Therapeutics LLC.
heFH Pipeline Drugs Market Analysis, by Companies
To know more about the companies in the heFH pipeline drugs market, download a free report sample
heFH Pipeline Drugs Market Report Overview
| Key Targets | Proprotein Convertase Subtilisin/Kexin Type 9, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Angiopoietin Related Protein 3, ATP Citrate Synthase (ATP Citrate, Cholesteryl Ester Transfer Protein, and Type 1 Angiotensin II Receptor |
| Key Mechanisms of Action | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Angiopoietin Related Protein 3 Inhibitor, ATP Citrate Synthase (ATP Citrate Inhibitor, Cholesteryl Ester Transfer Protein Inhibitor, and Type 1 Angiotensin II Receptor Antagonist |
| Key Routes of Administration | Subcutaneous, Intravenous, and Oral |
| Key Molecule Types | Monoclonal Antibody, Gene Therapy, Small Molecule, Antisense RNAi Oligonucleotide, and Fusion Protein |
| Leading Companies | Verve Therapeutics Inc, Regeneron Pharmaceuticals Inc, Akeso Inc, Amgen Inc, Beijing Mabworks Biotech Co Ltd, Daewoong Pharmaceutical Co Ltd, Epicrispr Biotechnologies Inc, Esperion Therapeutics Inc, Innovent Biologics Inc, and LIB Therapeutics LLC |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- Reviews of pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amgen Inc
Beijing Mabworks Biotech Co Ltd
Daewoong Pharmaceutical Co Ltd
Epicrispr Biotechnologies Inc
Esperion Therapeutics Inc
Innovent Biologics Inc
LIB Therapeutics LLC
NeuroBo Pharmaceuticals Inc
NewAmsterdam Pharma BV
Novartis AG
Regeneron Pharmaceuticals Inc
Shanghai Junshi Bioscience Co Ltd
Verve Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the heFH pipeline drugs market?
Some of the key targets of the heFH pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Angiopoietin Related Protein 3, ATP Citrate Synthase (ATP Citrate, Cholesteryl Ester Transfer Protein, and Type 1 Angiotensin II Receptor.
-
What are the key mechanisms of action of the heFH pipeline drugs market?
Some of the key mechanisms of action of the heFH pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Angiopoietin Related Protein 3 Inhibitor, ATP Citrate Synthase (ATP Citrate Inhibitor, Cholesteryl Ester Transfer Protein Inhibitor, and Type 1 Angiotensin II Receptor Antagonist.
-
What are the key routes of administration in the heFH pipeline drugs market?
The key routes of administration in the heFH pipeline drugs market are subcutaneous, intravenous, and oral.
-
What are the key molecule types in the heFH pipeline drugs market?
The key molecule types in the heFH pipeline drugs market are monoclonal antibody, gene therapy, small molecule, antisense RNAi oligonucleotide, and fusion protein.
-
Which are the leading companies in the heFH pipeline drugs market?
Some of the leading companies in the heFH pipeline drugs market are Verve Therapeutics Inc, Regeneron Pharmaceuticals Inc, Akeso Inc, Amgen Inc, Beijing Mabworks Biotech Co Ltd, Daewoong Pharmaceutical Co Ltd, Epicrispr Biotechnologies Inc, Esperion Therapeutics Inc, Innovent Biologics Inc, and LIB Therapeutics LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Metabolic Disorders reports